시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 윌름스 종양 단백질 시장 보고서(2025년)
Wilms Tumor Protein Global Market Report 2025
상품코드 : 1695308
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 200 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,324,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,141,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,958,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

윌름스 종양 단백질 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 연평균 성장률(CAGR) 6.2%로 43억 5,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 맞춤형 의료에 대한 접근 방식, 유전체 및 단백질체학 연구의 발전, 환자 옹호 및 지원 이니셔티브, 정밀의료에 대한 규제 당국의 지원, 바이오마커 검사의 통합에 기인합니다. 예측 기간 동안 주요 동향으로는 조기 발견 및 스크리닝 프로그램의 중요성, 진단 분석의 규제 준수, 환자 옹호 및 인식 제고, 차세대 시퀀싱(NGS) 통합, 진단 서비스의 세계 확장 등이 있습니다.

신장암 발병률의 증가는 당분간 윌름스 종양 단백질 시장의 성장을 견인할 것으로 예상됩니다. 신장암은 신장 조직 내 비정상적인 세포 증식을 특징으로 하며, 특히 종양이 미세하거나 생검이 어려운 경우 WT1 발현 분석의 혜택을 받을 수 있습니다. 예를 들어, 미국 암협회가 2023년 1월에 보고한 바와 같이, 미국에서는 2023년에 약 81,800건의 신장암이 새로 발생하여 14,890명이 사망했습니다. 또한 영국 암연구협회(Cancer Research UK)의 예측에 따르면, 영국에서는 2038년부터 2040년까지 매년 21,900명의 신장암 환자가 새로 발생할 것으로 추정됩니다. 이에 따라 신장암 환자 증가는 윌름스 종양단백질 시장의 성장을 크게 촉진할 것으로 예상됩니다.

맞춤의료에 대한 수요 증가는 윌름스 종양 단백질(WT1) 시장의 성장 궤도를 촉진할 것으로 예상됩니다. WT1은 암 면역치료의 유망한 표적 항원으로서 암환자에 대한 WT1의 단백질 발현과 임상적 상관관계에 기반한 맞춤형 면역치료제를 개발할 수 있습니다. 맞춤형 면역치료제 개발이 가능합니다. 예를 들어, 2022년 미국 식품의약국(FDA)은 12개의 맞춤형 의약품을 승인했으며, 이는 새로 승인된 치료용 분자 실체의 약 34%를 차지합니다. 따라서 맞춤형 의료에 대한 수요 증가는 윌름스 종양 단백질(WT1) 시장의 성장을 촉진하는 중요한 요인으로 작용하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

ksm
영문 목차

영문목차

Wilms Tumor Protein (WT1) is a specific protein encoded by the WT1 gene, playing a critical role in various cellular processes, including normal kidney development during embryogenesis. Located on chromosome 11p13, the WT1 gene is expressed in several tissues, with particularly high levels in the developing kidney and the gonads. Wilms Tumor Protein plays an essential role in the normal development of the urogenital system and regulates the expression of numerous target genes.

The main types of products related to Wilms Tumor Protein include antibodies, assay kits, recombinant proteins, and others. Antibodies, also known as immunoglobulins, are proteins produced by the immune system in response to the presence of foreign substances, such as bacteria, viruses, or other pathogens. Various detection methods, such as immunohistochemistry (IHC), enzyme-linked immunosorbent assay (ELISA), western blotting, polymerase chain reaction (PCR), and others, are applied in cancer diagnosis, cancer treatment, research and development, and other applications. End users include hospitals, diagnostic laboratories, research institutes, and others.

The wilms tumor protein market research report is one of a series of new reports from The Business Research Company that provides wilms tumor protein market statistics, including wilms tumor protein industry global market size, regional shares, competitors with a wilms tumor protein market share, detailed wilms tumor protein market segments, market trends and opportunities, and any further data you may need to thrive in the wilms tumor protein industry. This wilms tumor protein market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The wilms tumor protein market size has grown steadily in recent years. It will grow from $3.27 billion in 2024 to $3.42 billion in 2025 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to cancer incidence and diagnosis, rising awareness and screening programs, collaborations in cancer care.

The wilms tumor protein market size is expected to see strong growth in the next few years. It will grow to $4.35 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to personalized medicine approaches, genomic and proteomic research advances, patient advocacy and support initiatives, regulatory support for precision medicine, integration of biomarker testing. Major trends in the forecast period include focus on early detection and screening programs, regulatory compliance in diagnostic assays, patient advocacy and awareness initiatives, integration of next-generation sequencing (ngs), global expansion of diagnostic services.

The escalating incidence of kidney cancers is poised to drive the growth of the Wilms tumor protein market in the foreseeable future. Kidney cancer, characterized by abnormal cell growth within kidney tissue, can benefit from WT1 expression analysis, especially in cases where tumors are minute or challenging to biopsy. For instance, as reported by the American Cancer Society in January 2023, approximately 81,800 new cases of kidney cancer and 14,890 deaths were recorded in 2023 in the United States. Additionally, projections by Cancer Research UK suggest an estimated 21,900 new cases of kidney cancer annually in the UK by 2038-2040. Consequently, the increasing instances of kidney cancers are expected to significantly propel the growth of the Wilms tumor protein market.

The expanding demand for personalized medicine is anticipated to fuel the growth trajectory of the Wilms tumor protein (WT1) market. Personalized medicine represents an innovative healthcare approach considering individual genetic, environmental, and lifestyle variations when designing patient-specific treatment strategies. WT1 serves as a promising target antigen for cancer immunotherapy, allowing the development of tailored immunotherapy based on its protein expression and clinical correlations for cancer patients. For example, in 2022, the Food and Drug Administration (FDA) in the United States approved 12 personalized medicines, constituting approximately 34% of all newly approved therapeutic molecular entities. Hence, the increasing demand for personalized medicine stands as a significant driver propelling the growth of the Wilms tumor protein (WT1) market.

Key companies in the Wilms tumor protein market are directing efforts toward developing advanced detection methodologies, such as the enzyme-linked immunosorbent assay (ELISA), to offer dependable services to their market clientele. ELISA, a highly sensitive and specific method, employs specialized enzymes that bind to antibodies in the blood, detecting Host Cell Proteins (HCPs). For instance, in February 2023, Charles River Laboratories International Inc., a US-based entity specializing in novel drug and therapeutic development, introduced an Enzyme-Linked Immunosorbent Assay (ELISA) Kit designed for the detection and quantification of residual Host Cell Proteins (HCP). This innovative HCP-ELISA kit from Charles River utilizes avian IgY antibodies as its primary detection method. These specific antibodies, exclusively produced by AVS Bio from Specific-Pathogen-Free Chicken (SPF) Eggs, form a crucial component of this novel detection system.

In December 2023, Danaher Corporation, a U.S.-based conglomerate and a leading innovator in life sciences and diagnostics, acquired Abcam plc for $5.7 billion. Through this acquisition, Danaher Corporation aims to strengthen its life sciences capabilities by utilizing Abcam's advanced antibody portfolio to accelerate drug discovery and expand its market reach. Abcam plc, a U.K.-based biotechnology company, supplies antibodies that target the Wilms Tumor Protein (WT1) for cancer research and diagnostic applications.

Major companies operating in the wilms tumor protein market report are Thermo Fisher Scientific Inc., Abbott Laboratories, Glaxosmithkline PLC, F. Hoffmann-La Roche Ltd., Otsuka Holdings Co Ltd., Agilent Technologies Inc., Illumina Inc., Sumitomo Dainippon Pharma Co Ltd., PerkinElmer Inc., ZS Genetics Inc., Tecan Trading AG, QIAGEN NV, Abcam PLC, Hamilton Company, BioLegend Inc., Oxford Nanopore Technologies PLC, Pacific Biosciences of California Inc., Sino Biological Inc., LI-COR Inc., Cell Signaling Technology Inc., Genetex Inc., Proteintech Group Inc., Zymo Research Corporation, Santa Cruz Biotechnology Inc., Novus Biologicals LLC, Inovio Pharmaceuticals Inc., OriGene Technologies Inc., Macrogen Inc., Boster Biological Technology, Vaximm Ag, Fitzgerald Industries International

North America was the largest region in the wilms tumor protein market in 2024. The regions covered in the wilms tumor protein market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the wilms tumor protein market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The Wilms tumor protein market consists of revenues earned by entities by providing services such as genetic testing and counseling, cancer diagnosis, and treatment, and pediatric oncology services. The market value includes the value of related goods sold by the service provider or included within the service offering. The wilms tumor protein market also includes sales of polymerase chain reaction (PCR) primers and probes, and research kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Wilms Tumor Protein Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on wilms tumor protein market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for wilms tumor protein ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The wilms tumor protein market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Wilms Tumor Protein Market Characteristics

3. Wilms Tumor Protein Market Trends And Strategies

4. Wilms Tumor Protein Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Wilms Tumor Protein Growth Analysis And Strategic Analysis Framework

6. Wilms Tumor Protein Market Segmentation

7. Wilms Tumor Protein Market Regional And Country Analysis

8. Asia-Pacific Wilms Tumor Protein Market

9. China Wilms Tumor Protein Market

10. India Wilms Tumor Protein Market

11. Japan Wilms Tumor Protein Market

12. Australia Wilms Tumor Protein Market

13. Indonesia Wilms Tumor Protein Market

14. South Korea Wilms Tumor Protein Market

15. Western Europe Wilms Tumor Protein Market

16. UK Wilms Tumor Protein Market

17. Germany Wilms Tumor Protein Market

18. France Wilms Tumor Protein Market

19. Italy Wilms Tumor Protein Market

20. Spain Wilms Tumor Protein Market

21. Eastern Europe Wilms Tumor Protein Market

22. Russia Wilms Tumor Protein Market

23. North America Wilms Tumor Protein Market

24. USA Wilms Tumor Protein Market

25. Canada Wilms Tumor Protein Market

26. South America Wilms Tumor Protein Market

27. Brazil Wilms Tumor Protein Market

28. Middle East Wilms Tumor Protein Market

29. Africa Wilms Tumor Protein Market

30. Wilms Tumor Protein Market Competitive Landscape And Company Profiles

31. Wilms Tumor Protein Market Other Major And Innovative Companies

32. Global Wilms Tumor Protein Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Wilms Tumor Protein Market

34. Recent Developments In The Wilms Tumor Protein Market

35. Wilms Tumor Protein Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기